Study: Crystal structures of fluorescent proteins determined

Researchers have determined the crystal structures of red fluorescent protein TagRFP and its derivative, the blue fluorescent protein mTagBFP and have proposed a chemical mechanism by which the red color in fluorescent proteins is formed from blue, according to study results published April 23 in Chemistry & Biology.

Vladislav V. Verkhusha, PhD, associate professor of anatomy and structural biology at Albert Einstein College of Medicine in Bronx, N.Y., demonstrated that mTagBFP was a new type of the chromophore, N-[(5-hydroxy-1H-imidazole-2-yl) methylidene] acetamide.

The researchers also proposed a chemical mechanism in which the red-like chromophore is formed via the mTagBFP-like blue intermediate.

“Knowing the molecular structures of the chromophores--the part of fluorescent protein molecules that gives them their color--we can now do hypothesis-based designing of new probes, instead of relying on random mutations,” said Verkhusha.

Researchers can now follow only two or three proteins at a time. “To understand many cellular functions, you would like to follow dozens of different proteins, so the more colors we can develop, the better,” said study co-author Steven C. Almo, PhD, professor of biochemistry and of physiology and biophysics at Albert Einstein.

Using this new information, Verkhusha’s laboratory has already designed a variety of new fluorescent proteins that can glow in colors ranging from blue to far-red and recently viewed individual breast cancer cells for several days at a time to study metastasis.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.